SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This study is being performed to establish the association between absorbed dose to tumor and response and absorbed dose to normal organs and toxicity following Lu177-PSMA radioligand therapy
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Zaplanowana terapia Lu-177 PSMA w zaawansowanym raku prostaty
- •Stabilny stan zdrowia oceniony przez specjalistę medycyny nuklearnej
- •Płeć męska
- •Wiek 18 lat lub więcej
- •Chęć i możliwość podpisania zgody na udział w badaniu
✗ Disqualifies
- •Niemożność leżenia nieruchomo wystarczająco długo do wykonania badań obrazowych
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 27, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (1)
University of Michigan Comprehensive Cancer Center
Ann Arbor, United States
Trial contact
James Pool
Yuni K. Dewaraja
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/28/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.